Novartis annoiunces positive data from Phase III studies of AIN457 in clearing skin of psoriasis patients
This data was presented at the European Association of Dermatology and Venereology (EADV) Congress, in Amsterdam, Netherlands. Secukinumab’s new mode of action stops interleukin-17A (IL-17A), which plays a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.